TXR 1G IV INJ TXR 500MG IM INJ TXR 500MG IV INJ TXR INJ 2G IV

Product Overview

TXR Injection is a broad-spectrum, long-acting parenteral third-generation cephalosporin antibiotic containing Ceftriaxone Sodium. Engineered for immediate systemic bioavailability via Intravenous (IV) injection/infusion or Intramuscular (IM) injection, TXR delivers potent bactericidal action against a comprehensive range of Gram-negative and Gram-positive aerobic and anaerobic bacterial pathogens. It is widely indicated for severe lower respiratory tract infections, bacterial meningitis, intra-abdominal infections, complicated urinary tract infections, bone and joint infections, pelvic inflammatory disease, skin/soft tissue infections, bacterial septicemia, and surgical infection prophylaxis.

Key Benefits

• Broad-Spectrum Bactericidal Coverage: Highly effective against resistant Gram-negative bacilli (including Enterobacteriaceae and Haemophilus influenzae) and Gram-positive pathogens (Streptococcus pneumoniae).

• Extended Systemic Half-Life: Features a prolonged elimination half-life that permits convenient once-daily parenteral administration in most clinical indications.

• High Meningeal Penetration: Crosses inflamed blood-brain barriers rapidly, serving as a primary line of treatment for bacterial meningitis.

• Dual Route & Flexible Dosing (500mg to 2g): Offered in specific IV and IM formulations across 500mg, 1g, and 2g strengths to cater to pediatric, adult, and critical inpatient care.

• Surgical Infection Prophylaxis: Effective single-dose pre-operative prophylaxis to prevent post-operative surgical site infections.

How It Works

TXR Injection (Ceftriaxone Sodium) exerts its bactericidal action by selectively binding to penicillin-binding proteins (PBPs) located on the inner bacterial cell membrane. This binding blocks the final transpeptidation step of peptidoglycan synthesis, disrupting the structural assembly of the bacterial cell wall. The resulting osmotic instability triggers cell wall rupture, autolytic enzyme activation, and rapid cell death of dividing bacterial organisms.

WooCommerce Attribute / Variation Details

Variation 1: TXR 500MG IM INJ

• SKU: TXR-INJ-500-IM

• Short Description: Formulated specifically for deep intramuscular administration; ideal for pediatric outpatient care, uncomplicated gonorrhea, and mild-to-moderate community infections.

• Key Active Ingredient: Ceftriaxone Sodium — equivalent to 500mg Ceftriaxone per vial (reconstituted with Lidocaine Hydrochloride solution to minimize injection site pain).

• Target Indications: Uncomplicated gonococcal infections, pediatric mild-to-moderate respiratory/urinary infections, and acute otitis media.

• Standard Dosage: Administer 500mg deeply into a large muscle mass once daily, or as prescribed by a healthcare provider.

Variation 2: TXR 500MG IV INJ

• SKU: TXR-INJ-500-IV

• Short Description: Intravenous formulation intended for pediatric inpatient care, step-down parenteral therapy, and moderate systemic infections.

• Key Active Ingredient: Ceftriaxone Sodium — equivalent to 500mg Ceftriaxone per vial (reconstituted with Sterile Water for Injection).

• Target Indications: Pediatric systemic infections, complicated UTI, and moderate lower respiratory tract infections.

• Standard Dosage: Administer 500mg slowly via direct IV injection over 2 to 4 minutes once daily.

Variation 3: TXR 1G IV INJ

• SKU: TXR-INJ-1G-IV

• Short Description: Standard adult intravenous strength for severe community-acquired infections, pre-operative surgical prophylaxis, and inpatient care.

• Key Active Ingredient: Ceftriaxone Sodium — equivalent to 1g Ceftriaxone per vial.

• Target Indications: Community-acquired pneumonia, acute pyelonephritis, intra-abdominal infections, skin/soft tissue infections, and perioperative prophylaxis.

• Standard Dosage: Administer 1g to 2g intravenously once daily (or 1g IV given 30 to 90 minutes prior to surgery).

Variation 4: TXR INJ 2G IV

• SKU: TXR-INJ-2G-IV

• Short Description: High-potency intravenous strength reserved for critical inpatient care, severe bacterial meningitis, and life-threatening septicemia.

• Key Active Ingredient: Ceftriaxone Sodium — equivalent to 2g Ceftriaxone per vial.

• Target Indications: Bacterial meningitis, severe hospital-acquired septicemia, neutropenic fever, and severe bone and joint infections.

• Standard Dosage: Administer 2g once daily (or 2g every 12 hours for bacterial meningitis) via slow IV infusion over 30 minutes.

General Product Details (Shared across variations)

Key Active Ingredients

• Ceftriaxone Sodium (500mg / 1g / 2g): Parenteral third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.

Directions for Use

1. Reconstitution:

   • For IM Route (TXR 500mg IM): Reconstitute strictly with 1% Lidocaine Hydrochloride solution to reduce local injection pain. Warning: Solutions containing Lidocaine must NEVER be administered intravenously.

   • For IV Route (TXR 500mg IV, 1g IV, 2g IV): Reconstitute with Sterile Water for Injection or 0.9% Sodium Chloride Injection. For IV infusion (1g/2g), dilute reconstituted solution further in 50ml to 100ml of compatible IV fluids (0.9% Normal Saline or 5% Dextrose).

2. Administration:

   • Direct IV Injection: Administer slowly over 2 to 4 minutes.

   • IV Infusion: Infuse over at least 30 minutes.

   • IM Injection: Administer via deep intramuscular injection into a large muscle mass (gluteal region).

3. Calcium Compatibility Warning: Do NOT mix or administer Ceftriaxone simultaneously with calcium-containing IV solutions (such as Ringer’s or Hartman’s solution), as precipitation may occur.

4. Professional Healthcare Use: Must be administered exclusively by qualified medical personnel in a clinical or hospital setting.

Precautions

• Prescription-Only Parenteral: Strictly for professional healthcare administration; do not self-administer.

• Hypersensitivity Alert: Carefully screen patients for prior severe hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactam antibiotics.

• Hyperbilirubinemic Neonates: Contraindicated in hyperbilirubinemic neonates and premature infants due to the risk of bilirubin encephalopathy.

• Gallbladder & Renal Sludging: High-dose or prolonged therapy may cause transient gallbladder biliary sludging or renal precipitates; monitor accordingly.

• Consult an attending physician before use during pregnancy or lactation.

• Keep out of reach of children.

Storage Instructions

Store the un-reconstituted dry powder vial in a cool, dry place below 30°C, protected from direct sunlight and heat. Once reconstituted, solutions remain stable for up to 6 hours at room temperature (25∘C) or up to 24 hours under refrigeration (2∘C to 8∘C). Do not freeze.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to providing high-potency anti-infective parenteral formulations that combat multi-drug resistant pathogens and support critical inpatient recovery.